Relmada Therapeutics, Inc.
NASDAQ:RLMDBiotechnology
-$0.06 today
- Market cap
- $304.61M
- Beta
- 0.39
- P/E (TTM)
- -9.6
- EPS (TTM)
- -$0.68
Volume 1.86M
Average 1.24M
RLMD Operating Cash Flow
Cash generated by the company's core business operations during the period.
Relmada Therapeutics, Inc.NASDAQ: RLMD
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $15.07M (cash outflow) fell 16.6% year over year, ahead of the -24.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 3.2% from the prior quarter. Over 3 fiscal years it compounded at -23.9% a year.
Context
- Operating cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -16.6% holds above the trailing-twelve-month pace of -24.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (45.79M) USD
- Year-over-year change
- +11.5%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.79M) | +11.5% |
| FY2024 | 2024-12-31 | (51.76M) | -0.2% |
| FY2023 | 2023-12-31 | (51.66M) | +50.2% |
| FY2022 | 2022-12-31 | (103.8M) | -13.0% |
| FY2021 | 2021-12-31 | (91.87M) | — |
Operating Cash Flow vs competitors
How RLMD compares with its peers on the latest reported figures
- RLMD's LTM Mar 2026 operating cash flow of $42.79M is the 8th largest of the 9 companies compared; the peer median is $69.83M.
- Its year-over-year change of -24.7% is the lowest of 9, against a peer median of +0.5%.
- Over three fiscal years its annual growth of -23.9% compares with a peer median of +26.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $157.64M | +312.0% | -28.4% | 238.3% | |
| LTM Mar 2026 | $122.01M | +2.4% | +26.7% | 1335.5% | |
| LTM Mar 2026 | $91.34M | -3.8% | +28.6% | — | |
| LTM Mar 2026 | $81.33M | -1.5% | +9.6% | — | |
| LTM Mar 2026 | $74.99M | +40.5% | +4.9% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $64.67M | -5.1% | +28.3% | — |
CBUSCibus, Inc. | LTM Mar 2026 | $50.25M | -10.9% | +37.7% | 1172.4% |
| LTM Mar 2026 | $42.79M | -24.7% | -23.9% | — | |
| LTM Mar 2026 | $15.26M | +146.0% | — | 6.0% | |
| Peer median (excluding RLMD) | $69.83M | +0.5% | +26.7% | 705.3% | |
Competitors are the stored peer set for RLMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (125.75M) | (157.04M) | (98.79M) | (79.98M) | (57.39M) |
| Depreciation & Amortization | 1.26K | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 40.49M | 44.19M | 43.81M | 30.19M | 14.96M |
| Change in Working Capital | (7.86M) | 10.59M | 3.08M | (1.58M) | (3.95M) |
| Accounts Receivables | 79.46K | (426.06K) | 512.43K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.85M | 421.04K | (1.76M) | 624.55K | (2.56M) |
| Other Working Capital | (10.79M) | 10.6M | 4.32M | (2.21M) | (1.39M) |
| Other Non-Cash Items | 1.25M | (1.55M) | 241.16K | (381.66K) | 586.18K |
| Operating Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
| Capital Expenditures | 0 | 0 | (4) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (222.98M) | (47.29M) | (90.46M) | (12.08M) | (83.83M) |
| Sales of Investments | 168.86M | 67.03M | 140.92M | 63.64M | 35.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (54.12M) | 19.73M | 50.45M | 51.56M | (48.14M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 185.31M | 42.73M | 0 | 246.75K | 93.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.63M | 2.29M | (98.46K) | (287.09K) | (73.02K) |
| Financing Cash Flow | 187.94M | 45.02M | (98.46K) | (40.34K) | 93.56M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.95M | (39.05M) | (1.3M) | (234.54K) | (360.49K) |
| Free Cash Flow | (91.87M) | (103.8M) | (51.66M) | (51.76M) | (45.79M) |
Relmada Therapeutics, Inc.
NASDAQ:RLMD
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.